CA2634749A1 - Process for preparing a synthetic intermediate for preparation of branched nucleosides - Google Patents

Process for preparing a synthetic intermediate for preparation of branched nucleosides Download PDF

Info

Publication number
CA2634749A1
CA2634749A1 CA002634749A CA2634749A CA2634749A1 CA 2634749 A1 CA2634749 A1 CA 2634749A1 CA 002634749 A CA002634749 A CA 002634749A CA 2634749 A CA2634749 A CA 2634749A CA 2634749 A1 CA2634749 A1 CA 2634749A1
Authority
CA
Canada
Prior art keywords
lactone
deoxy
alkyl
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002634749A
Other languages
French (fr)
Other versions
CA2634749C (en
Inventor
Benjamin Alexander Mayes
Adel Moussa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idenix Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2634749A1 publication Critical patent/CA2634749A1/en
Application granted granted Critical
Publication of CA2634749C publication Critical patent/CA2634749C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals

Abstract

A process is provided for the preparation of a key intermediate in the preparation of 2'-branched nucleoside compounds.
The process includes contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone and optionally into a 2- deoxy-2-halo-2-C-disubstituted ribono- 1,4-lactone.

Description

Process for Preparing a Synthetic Intermediate for Preparation of Branched Nucleosides Cross Reference This application claims priority to U.S. Provisional Application No.
60/753,507 'filed Deceniber 23, 2005, the disclosure of which is incorporated by reference.

Field of the Invention This application relates to methods for the preparation of a synthetic intermediate in a process for preparing 2'-C-alkyl-2'-halo-nucleoside analogues, which are important as anti-viral, anti-cancer, and antibacterial agents.

Background of the Invention A process for preparing a halogen-substituted ribonolactone intermediate that is useful in the synthesis of a 2'-C-metliyl-2'-halo nucleoside analogue presents ongoing challenges, particularly where the halogen atom is fluorine.
A key intermediate in the preparation of sugar analogues used in the synthesis of nucleosides and vitamins is 2-C-methyl-D-ribono-lactone. As early as 1880, Scheibler described a process for preparing the lactone (John Sowden, "The Saccharinic Acids" in Adv. Carbohydrate Chem. 12:43-46 (1957), citing C.
Scheibler, Berichte 13:2212 (1880)). Unfortunately, product yields were only approximately 10% (Id.). At about the same time, H. Kiliani synthesized 2-methyl-D-ribonolactone by treating D-fructose with calcium hydroxide (H. Kiliani, Berichte, 15:2953 (1882), as cited in F.J. Lopez-Herrera et al., J. Carbohydrate Cherrzistry, 13(5):767-(1994)). However, the process required months to run to completion and product yield was also only approximately 10% (Id. at 768). Kiliani's process, however, enabled him to establish the positions of important functional groups on the compound (John Sowden, "The Saccharinic Acids" in Adv. Carbohydrate Chem.
12:43-46 (1957), citing H. Kiliani, Ann., 213:361 (1883)). '.
In the early 1960s, Whistler and BeMiller attempted to improve upon Kiliani's synthesis (Roy L. )Nhistler and J.N. BeMiller, "a-D-Glucosaccharino-1,4-lactone" in Methods in Carbohydrate Chernistry, 2:484-485 (1963)). Whistler and BeMiller added boiling water and calcium hydroxide to D-fructose, flushed the system with nitrogen gas, and repeated the same process. The mixture then was maintained for 6-8 weeks, after which it was treated with CO2 and oxalic acid dihydrate, and filtered under pressure. The residue was washed repeatedly to a syrup-like consistency, and filtrates combined; solvent evaporated under reduced pressure and the resultant product allowed to crystallize under refrigeration. The final product yield was still only about 10% Id. at 485) and the process took two months to complete.

BE 731271 and GB 1189973, assigned to Deutsche Akademie der Wissenchaften, disclosed a process for preparing 3'-fluoronucleosides by reacting a nucleoside with a fluorinating agent such as HF in an organic solvent like THF
at temperatures ranging from 130-160 C.

In an attempt to improve product yields, Lopez-Aparicio et al. reported the synthesis of 2-C-methyl-D-ribono-1,4-lactone from 2,3-O-isopropylidene-D-glycer-aldehyde as an alternative to the Kiliani synthesis (Lopez-Aparicio et al., Carbohydrate Res., 129:99 (1984), as cited in F.J. Lopez-Herrera et al., J.
Carbohydrate Chemistry, 13(5):767-775 (1994) at 768-769). The process of Lopez-Aparicio included condensing 2,3-O-isopropylidene-D-glyceraldehyde with (1-methoxy-carbonyl-ethylidene) triphenylphosphorane to produce methyl E-(S)-4,5-dihydroxy-4,5-O-isopropylidene-2-methyl-2-pentenoate; hydrolyzing (in HCl) and photochemically isomerizing the pentenoate; lactonizing the pentenoate product to produce a butenolide; tritylating the butenolide at C-5 by reaction with trityl-chloride and pyridine, followed by cis-hydroxylation with potassium permanganate and methylene chloride in the presence of a crown ether. Final removal of the trityl (triphenylmethyl) group was achieved by reaction with TFA (trifluoroacetic acid) (Ld.
at 768). Lopez-Aparicio et al. reported product yields of ribonolactone at about 80%, but others were not able to reproduce this figure based on the gram mass amounts of materials provided in the experimental section of their publication. Instead, calculations indicated a percent yield of about 36% ribonolactone. In addition, the process of Lopez-Aparicio et al. was far more complex than the Kiliani synthesis, required the use of toxic reagents such as potassium permanganate and specialized equipment for irradiation to attain photochemical isomerization, and had a minimum of 60 hours reaction time (Id. at 768, 770-772).
None of the foregoing approaches addressed the problem of preparing 2'-C-branched or 2'-disubstituted ribonucleoside analogues.

In 1989, the Asahi Glass Company Ltd. reported the synthesis of fluoronucleosides that had antiviral and antitumor effects (JP 02270864 and JP
01100190). These 'nucleosides were prepared by treating a 9-(alpha-fluoro-4-beta-hydroxy-l-beta-cyclopentyl)pyrimidine derivative with trifluoromethanesulphonyl chloride, p-toluenesulphonyl chloride, methanesulphonyl chloride or imidazolylsulphonyl chloride in the presence of a base, followed by reduction (JP
02270864). In a second synthetic method, 2',3'-deoxy-2',3'-didehydro-2'-fluoronucleosides were obtained by the dehydrogenation of a 2'-deoxy-2'-fluororibofuranosyl derivative, or by dehydrogenation of a 2',3'-dideoxy-2'-fluoro-3'-halo-ribonucleoside derivative (JP 0 1100190).

In 1990, Bobek et al. disclosed the synthesis of antiviral, antitumor, and antimicrobial arabinopyranosyl nucleoside derivatives that had a fluorine atom at the 2'-position of the pyranose ring (U.S. 4,918,056). These compounds were prepared by the condensation of a pyrimidine, purine, or 1,3-oxazine nucleobase with an hydroxyl group-blocked, acylated 2-deoxy-2,2-difluoro-D,-arabinopyranoside and/or an acylated 2-deoxy-2-bromo-2-fluoro-D-arabinopyranoside (Id.).

In 1997 Harry-O'Kuru et al. described a synthetic route for preparing 2'-C-branched ribonucleosides (Harry-O'Kuru et al., J. Org. Chem., 62:1754-9 (1997)).
Commercially available 1,3,5-tri-O-benzoyl-a-D-ribofuranose was used as the starting material, which was prepared from D-ribose or D-arabinose (D-arabinopyranose).
The 1,3,5-tri-O-benzoyl-a-D-ribofuranose was oxidized at the free 2-OH with Dess-Martin periodinane reagent, and produced 1,3,5-tri-O-benzoyl-2-keto-ribofuranose as well as its corresponding hydrate. The desired product and hydrate were stirred with excess MgSO4 and permitted to stand overnight. The mixture was then filtered and concentrated in order to produce a substantially pure ketone product. The resultant 2-ketosugar was treated with MeMgBr/TiC14 (or alternatively with MeTiC13, CHa=CHMgl3r/CeC13a or TMSC=CLi/CeC13), which produced an anomeric mixture of the desired 1,3,5-tri-O-benzoyl-2-substituted alkyl-, alkenyl- or alkynyl-ribofuranoside and its transesterified isomers, a- and fl-2,3,5-tri-O-benzoyl-substituted alkyl, alkenyl or alkynyl ribofuranoside in a nearly 5:3 ratio of desired product to isomeric forms (Id. at 1755). The 2-alkylated ribofuranosides then were converted to a single, desired product, 1,2,3,5-tetrabenzoyl-2-alkylribofuranoside, by treatment with benzoyl chloride, D1VIA.P and triethylamine in a reported approximately 70% yield with a(3/a ratio of 4:1 (Id.).

In 1998, Chambers et al. reported the synthesis of 2',3'-dideoxy-3'-fluorouridine compounds by reaction of a corresponding anhydronucleoside with hydrogen fluoride in the presence of an organo-iron compound and in an organic solvent (U.S. 5,717,086).

Recent reports of syntheses of 2' and/or 3' halonucleosides have been disclosed by Pharmasset, Inc., The University of Georgia Research Foundation, Inc., and Emory University.

WO 05/003147 (also US 2005/0009737) to Pharmasset, Inc., described the synthesis of 2'-C-methyl-2'-fluoro nucleoside analogues by one of two general synthetic routes: alkylating an appropriately modified carbohydrate compound, fluorinating it, and then coupling it to a desired nucleobase, or glycosylating a desired nucleobase to form a nucleoside, then alkylating the nucleoside, and finally fluorinating the preformed nucleoside. Pharmasset's first approach utilized a modified carbohydrate that was an hydroxyl group-protected lactone, which was alkylated with a reagent such as methyl lithium in an anhydrous solvent like THF, and then was reacted with a commercially available fluorinating agent like DAST or Deoxofluor, followed by a deprotection step. The reaction proceeded with inversion at the 2'-position such that the fluorine atom was in the "down" or ribo configuration.
Pharmasset's second synthetic route comprised the modification of a commercially available nucleoside whose hydroxyl groups were protected by protective groups known in the art.
The nucleoside was oxidized at the 2'-position to provide a 2'-ketone, and the 2'-ketone was reacted with an alkylating agent such as methyl lithium in THF at about 0 C. to afford a 2'(S) or 2'-methyl "down", 2'-hydroxyl "up" configured nucleoside tertiary alcohol. A fluorine atom then was introduced by reacting the nucleoside with a cornmercially available fluorinating reagent such as DAST in an anhydrous, aprotic solvent like toluene with inversion at the 2'-position to afford a 2'-C-methyl "up", 2'-fluoro "down" configuration of the nucleoside. However, by either synthetic route, Pharmasset's isolation and purification methods were impracticaUinefficient and product yield was very low in all examples provided.

PCT Publication No. WO 2006/031725 to Pharmasset, Inc. describes the synthesis of 2'-C-substituted-2'-deoxy-2'-halo nucleosides via the nucleophilic ring opening of a 5-memebered ring cyclic sulfate intermediate derived from 4,5-di-O-protected-2-methyl-2,3-dihydroxy-pentanoic acid with fluoride to produce a 2-methyl-2-fluoro 4,5-di-O-protected fluorinated acyclic sulfate ester compound.
The fluorinated sulfate ester is treated with acid to deprotect the 4,5-hydroxyl groups and cyclized to 2'-fluoro-2'-C-methyl-y-ribonolactone. The ribonolactone is then converted to the 2'-C-methyl-2'-deoxy-2'-halo nucleosides by reduction of the lactone and coupling with an appropriate base.

WO 2006/012440 to Pharmasset, Inc. describes the synthesis of 2'-C-substituted-2'-deoxy-2'-halo nucleosides via a 2'-fluoro-2'-C-substituted-y-ribonolactone intermediate. The 2'-flu6ro-2'-C-substituted-y-ribonolactone is formed by cyclization of a 2-fluoro-4,5-di-O-protected-2,3-dihydroxy-pentanoic acid ethyl ester intermediate upon treatment with acid. The fluorination reaction is achieved by treating 4,5-di-O-protected-2-hydroxy-3-0-protected-pentanoic acid ethyl ester with DAST.

Otto et al. reported the synthesis and use of beta-2' or beta-3'-halonucleosides for the treatment of HIV, hepatitis B, and undesired cellular proliferation (U.S.
6,949,522). The syntheses disclosed produced 2',3'-dideoxy, 3',3'-dihalo nucleosides from glyceraldehyde or a sugar ring starting material; 2',3'-dideoxy, 3'-halo nucleosides from a lactol starting material; and 2',3'-dideoxy-2'-halo nucleosides from glyceraldehyde as a starting material that proceeds via a lactone intermediate that is selectively reduced to afford a 2',3'-hydro product.

Clark et al. disclosed the synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine as an inhibitor of hepatitis C virus (Clark et al., J.
Med. Chem.
2005, 48:5504-5508). Synthesis of the product compound proceeded through N4-benzoyl-l-(2-methyl-3,5-di-O-benzoyl-(3-D-arabinofuranosyl)cytosine as a key intermediate, which was oxidized to the corresponding 2'-ketone derivative by reaction with trifluoroacetic anhydride in DMSO under Swern oxidation conditions.
The 2'-ketone derivative was reacted with methyllithium at -78 C in diethyl ether to afford protected ] -[2-C-methyl-3,5- -(tetraisopropyldisiloxane-l,3-diyl)1-(3-D-arabinofuranosyl]cytosine, and the 3',5'-silyl protecting group was removed by reaction in TBAF/acetic acid. Clark et al. warn against the use of DAST for fluorination of tertiary alcohol groups because the reaction is substrate specific and stereochemically unpredictable.

Shi et al. reported the syntheses and antiviral activities of a series of D-and L-2'-deoxy-2'-fluororibonucleosides in a hepatitis C replicon system (Shi et al., Bioorganic & Medicinal Chemistry (2005), 13:1641-1652). The halo-substituted nucleosides tested had a single halo substituent at the 2'-position on the nucleoside sugar, and were prepared by direct conversion of D-2,2'-anhydrocytidine to (2'R)-D-2'-deoxy-2'-fluorocytidine by reaction with potassium fluoride and crown ether according to the method of Mengel and Guschlbauer (Angew. Cizem. Int. Ed.
Engl.
1978, 17:525).

There remains a need for discovering improved synthetic routes and new synthetic intermediates in the preparation of 2'-C-methyl-2'-halo-nucleoside analogue derivatives.

It is an object of the present invention to provide a stereochemically predictable and reliable process for the selective addition of alkyl and halo substituents at the 2'-C-position of a nucleoside analogue.
. ,.

It is another object of the present invention to provide an efficient process that utilizes a minirimum number of steps -and a readily available, inexpensive starting material for preparing a key intermediate in the synthesis of a 2'-C-methyl-2'-ha1o-nucleoside analogue.

It is still another object of the present invention to provide a process that employs non-toxic reagents and provides the key intermediate in good percent product yield.

Summary of the Invention Historically, the addition of halogen atoms, particularly fluorine, has presented a challenge for researchers attempting to find a direct and simplified process for adding the atom to a precursor compound to provide a 2-deoxy-2-halo-2-C-substituted-D-ribono-1,4-lactone that then can be used in the synthesis of nucleoside analogue derivatives. In particular, the desired stereochemistry of the halogen and other substituents (typically alkyl) at the 2 position has been difficult to produce because of the competition between substitution with the halogen and elimination of the leaving group at the tertiary carbon to produce a byproduct with an exocyclic double bond. A process that allows nucleophilic substitution with a halogen atom to overtake elimination in this balance has been lacking. It now has been found that a halogen, and particularly a fluorine atom can be efficiently introduced at a tertiary center of an isopropylidene-arabinono-1,5-lactone to afford a 2-C-substituted-fluoro-ribonolactone using the process provided herein.
In one embodiment, it was surprisingly found that 2-deoxy-2-fluoro-2-C-substituted lactone compounds can be produced in high yields by nucleophilic displacement on 3,4-0-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone or a halogenated derivative thereof using certain fluorinating reagents under anhydrous conditions.
In one embodiment, the invention provides a process of producing a 2-halo, and particularly 2-fluoro-2-C-substituted-1,5-lactone compound which includes:
a) providing a compound of structure (i) or (ii) ,is 0 1 O
R1 OR Ri X

or where OR is a suitable leaving group; R' is C1_14 alkyl, Cl-4 lower alkyl, C3_$ cycloalkyl, alkenyl including vinyl, alkynyl, including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle; and X
is a halogen atom;
b) contacting the compound with a fluorinating agent under anhydrous conditions.
In certain embodiments, the fluorinating agent is tris(dimethylamino)sulfonium difluorotrimethyl silicate (TASF).
In one embodiment, OR is a trifluoromethanesulfonate ester (triflate). In another embodiment, OR is a methanesulfonate ester (mesylate). In yet another embodiment, OR is a p-toluenesulfonate ester (tosylate).
In certain embodiment, the reaction contains less than 1%, less than 0.1 %, or less than 0.01% water.
In certain embodiments, the process produces a compound of Formula (II) O
HO'll, 0 HO~ F Rj (II) wherein R' is C1_1o alkyl, Cl.4 lower alkyl, C3.8 cycloalkyl, alkenyl including vinyl, alkynyl, including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle, in at least 40% or more yield.
In certain subembodiments, the compound of Formula (II) is produced in at least 50%, at least 55%, at least 60%, at least 70% or at least 80% or more yield.
In one subembodiment, R' in the compound of Formula (II) is methyl. In another embodiment, R' is ethyl. In another embodiment, R' is vinyl. In yet another embodiment, R' is -C=CRa, wherein R2 is Ci_ta alkyl, Ci.4 lower alkyl, C3_8 cycloalkyl, CF3, cyano, aryl, benzyl, or heierocycle. In another embodiment, R' cyano. In another embodiment, R' is benzyl. In yet another embodiment, R' is a heterocycle.
In one embodiment, the process further includes converting a compound of Formula (II) to a 1,4-lactone compound. In one embodiment, this conversion includes contacting the product from step (b) with an acid in a suitable organic solvent. In one embodiment, the acid is an organic acid. In one subembodiment, the acid is trifluoroacetic acid. In another subembodiment, the acid is acetic acid. In another embodiment, the acid is an aryl or alkyl sulfonic acid. In one subembodiment the solvent is 1,4-dioxane. In one embodiment, the 1,4-lactone product can be a 2-deoxy-2-halo-2-C-methyl-D-ribono-1,4-lactone of Formula (B):
O
HO-"'-C
ZO
R, HO F

(B), wherein R' is Ct_lo alkyl, Cl-4 lower alkyl, C3_$ cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle.
In certain embodiments, these compounds can be further modified by reduction of the lactone, derivitization of the resulting hydroxyl to a suitable leaving group and substitution with a base (including purine or pyrimidine bases) to provide a 2'-fluoro-2'-branched nucleoside including 2'-deoxy-2'-fluoro-2'-C-methyl-D-ribonofuranosyl nucleoside analogues.

Detailed Description of the Invention The present invention provides a process for preparing a compound of Formula (I) and Formula (II), which are a key intermediates in the synthesis of certain nucleoside analogues, including 2'-branched nucleoside analogs.

HOini O HOtli, p HO X1 R, HO' F R, (I) (II) wherein R' is C1_io alkyl, Cl-4 lower alkyl, C3_8 cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle; and Xl is halogen.
In one embodiment, the present invention further provides a process for preparing compounds of Foxmula (A) and Forniula (B), which are key intermediates in the synthesis of certain nucleoside analogues, including 2'-branched nucleoside analogs.

HO O O HO O O
y = R, R
HO ?e~ HO , (A) (B) wherein R' is Cl_lo alkyl, CI-4 lower alkyl, C3_$ cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle and X, is halogen.
DefinitiQns Whenever a range is referred to within the specification, such as CI _ao alkyl, the range independently refers to each element. For example, Cl_Io alkyl refers independently to CI-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, CS-alkyl, C6-alkyl, C7-alkyl, C8-alkyl, C9-alkyl and Cjo-alkyl.
The term alkyl, as used herein, "less otherwise specified, includes a saturated straight, branched, or cyclic hydrocarbon, including but not limited to those of C1 to Clo, and preferably CI-C4, including methyl, ethyl, propyl, isopropyl, cyclopropyl, methylcyclopropyl, butyl, isobutyl, t-butyl, sec-butyl, cyclobutyl, and (cyclopropyl)methyl. Cycloalkyl groups include groups with 3 to 10 carbons.
The alkyl group specifically includes fluorinated alkyls such as CF3 and other halogenated alkyls such as CH2CF2, CF2CF3, the chloro analogs, and the like.
The term alkenyl, as used herein, unless otherwise specified, includes a C2 to Clo hydrocarbon with at least one double bond, including but not limited to vinyl.
The term alkynyl, as used herein, unless otherwise specified, includes a C2 to Clo hydrocarbon with at least one triple bond, including but not limited to acetylene.
The term allenyl, as used herein, unless otherwise specified, includes a C3 to CIo hydrocarbon with at least two double bonds that share a central carbon atom.
The alkyl, alkenyl and alkynyl groups can be optionally substituted with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclic, carbocycle, alkoxy, heterocycloxy, heterocylalkoxy, aryloxy, arylalkoxy, heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, arnido, alkylamino, dialkylamino, arylamino, nitro, cyano, thiol, imide, sulfonic acid, sulfate, sulfonyl, sulfanyl,, sulfinyl, sulfamoyl, carboxylic ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, thioester, thioether, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, phosphinate, sulfonamido, carboxamido, hydroxamic acid, sulfonylimide, substituted or unsubstituted urea connected through nitrogen including but not limited to NHCONH2 and NHCONHR;
or any other desired functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
The term aryl, as used herein, and unless otherwise specified, includes phenyl, biphenyl, or naphthyl, and preferably phenyl. The term aryl includes heteroaryl groups. The aryl group can be optionally substituted with one or more of the moieties selected from the group consisting of alkyl, heteroaryl, heterocyclic, carbocycle, alkoxy, aryloxy, aryloxy, arylalkoxy, heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, alkylamino, dialkylarnino, arylamino, nitro, cyano, thiol, imide, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamoyl, carboxylic ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, thioester, thioether, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, phosphinate, sulfonamido, carboxamido, hydroxamic acid, sulfonylimide or any other desired functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., "Protective Groups in Organic Synthesis," John Wiley and Sons, Second Edition, 1991. Alternatively, adjacent groups on the aryl ring may combine to form a 5 to 7 membered carbocyclic, aryl, heteroaryl or heterocylic ring. In another embodiment, the aryl ring is substituted with an optionally substituted cycloalkyl (such as cyclopentyl or cylcohexyl), or an alkylene dioxy moiety (for example methylenedioxy).
The terrn heterocyclic or heterocycle includes nonaromatic cyclic groups that may be partially (contains at least one double bond) or fully saturated and wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring. The term heteroaryl or heteroaromatic, as used herein, includes aromatic groups that include at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
Nonlimiting examples of heterocylics and heteroaromatics are pyrrolidinyl, tetrahydrofuryl, piperazinyl, piperidinyl, morpholino, thiomorpholino, tetrahydropyranyl, imidazolyl, pyrolinyl, pyrazolinyl, indolinyl, dioxolanyl, or 1,4-dioxanyl. aziridinyl, furyl, furanyl, pyridyl, pyrimidinyl, benzoxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, indazolyl, 1,3,5-triazinyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzirnidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,3-oxadiazole, thiazine, pyridazine, or pteridinyl, wherein said heteroaryl or heterocyclic group can be optionally substituted with one or more substituent selected from the same substituents as set out above for aryl groups. Functional oxygen and nitrogen groups on the heteroaryl group can be protected as necessary or desired. Suitable protecting groups can include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl.
The term aralkyl, as used herein, and unless otherwise specified, refers to an aryl group as defined above linked to the molecule through an alkyl group as defined above. The aryl and alkyl portions can be optionally substituted as described above.
The term halo or halogen, as used herein, includes chloro, bromo, iodo and fluoro.
The term acyl, as used herein, refers to a group of the Formula C(O)R ', wherein R' is an alkyl, aryl, alkaryl or aralkyl group, or substituted alkyl, aryl, aralkyl or alkaryl, wherein these groups are as defined above.
The term purine or pyrimidine base includes, but is not limited to, adenine, Nb-alkylpurines, N6-acylpurines (wherein aayl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkylpurines, N2-alkyl-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-rnercaptopyrrnidine, uracil, 5-halouracil, including 5-fluorouracil, C5-alkylpyrimidines, C5-benzylpy.rimidines, C5-halopyrimidines, C5-vinylpyrimidine, C5-acetylenic pyrimidine, CS-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-amino-pyrimidine, N2 -alkylpurines, N2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired.
Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
The term "protected" as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, sulfur or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.

In one embodiment, the invention provides a process of producing a 2-fluoro-2-Gsubstituted-l,5-lactone compound of Formula (II) which includes:
O
HO'll, 0 HO~~ F Rj ; (II) a) providing a compound of structure (i) or (ii) Ol,1 clOR O 0,~~
R1~O. R1 X

or where OR is a suitable leaving group and X halogen; and Wherein R' is C1_10 alkyl, C14 lower alkyl, C3_8 cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, aralkyl including benzyl, or heterocycle; and b) contacting the compound with a fluorinating agent under conditions that allow replacement of the leaving group with a fluorine atom.
Leaving groups OR include but are not limited to arylsulfonate , including p-toluenesulfonate (tosylate), alkylsulfonate including methanefulfonate (mesylate), trifluoromethanesulfonate (triflate), allylsulfonate, 4-nitrobenzenesulfonate (nosylate), 4-bromobenzenesulfonate (brosylate), acetate, trifluoroacetate, arylsulfate, or alkylsulfate.
In preferred embodiments, step (b) is carried out under anhydrous conditions.
Anhydrous as used herein refers to the substantial absence of water, which is achieved, e.g., by conducting the reaction under an inert gas and using substantially dry reagents, for example with less than 1% or less than 0.1 !o water.

In one particular embodiment, the fluorinating agent is tris(dimethylamino)sulfonium difluorotrimethyl silicate (TASF).
Other, less preferred nucleophilic fluorinating agents include but are not limited to HF, HF-amine complexes, including HF-pyridine, sulfur tetrafluoride, KF, KF/crown ether, CaF, LiF, NaF, silver(I) fluoride, CsF, antimony (III) fluoride, antimony (V) fluoride, n-Bu4NF, cyanuric fluoride, tetrabutylammonium difluorotriphenylstannate, (diethylamino)sulfur trifluoride (DAST), morpholinosuifur trifluoride (Morpho-DAST), N,N-diethyl-1,1,2,3,3,3-heacafluroropropylamine, N,N-diethyl-1,2,3,3,3-pentafluroropropenamine, N,N-diethyl(2-chloro-1,1,2-trifluoroethyl)-amine and tetrabutylammonium difluorotriphenyl stannate.
Chlorinating agents include but are not limited to HC1, chloride salts, thionyl chloride, PC13, and PCl5. Brominating agents include but are not limited to HBr, bromide salts, thionyl bromide, PBr3, and PBr5. lodinating agents include but are not lirriited to HI
and iodide salts. TASF is a preferred fluorinating agent because of the optimized yield of the desired product.
Substitution of the leaving groups OR or X with halogen may be achieved with any nucleophilic halogenating agents known to those skilled in the art, however, TASF is a preferred halogenating agent because of the optimized yield of the desired product.
In certain embodiments, the process produces a compound of Formula (II) O
HO'li, O
' '..
HO Rj F (II) wherein R' C1_10 alkyl, Ct.4 lower alkyl, C3.8 cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, aralkyl including benzyl, or heterocycle, in at least 40% or more yield. In certain subembodiments, the compound of Formula (II) is produced in at least 50%, at least 55%, at least 60%, at least 70% or at least 80% or more yield.
In one subembodiment, R' in the compound of Formula (II) is methyl. In another subembodiment, R' is ethyl. In another subembodiment, R' is vinyl. In yet another subembodiment, R' is -C CR2,=wherein Rz is Ct_io alkyl, Ci-4 lower alkyl, C3_ 8 cycloalkyl, CF3a cyano, aryl, benzyl, or heterocycle. In another subembodiment, R' is -C-CH.
In one embodiment, the process further includes converting a compound of Formula (II) to a 1,4-lactone compound. In one embodiment, this conversion includes contacting the product from step (b) with a suitable acid. In one embodiment, the acid is an organic acid. Suitable acids include but are not limited to trifluoroacetic acid, trichloroacetic acid, acetic acid, methylsulfonic acid, p-toluenesulfonic acid, and trifluoromethylsulfonic acid. In one subembodiment, the acid is trifluoroacetic acid.
In another embodiment, the acid is methanesulfonic acid. In yet another embodiment, the acid is trichloroacetic acid. In one embodiment, the solvent is 1,4-dioxane. The 1,4-lactone product can be a 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone a compound of Formula (B):
O
HO o R, HO

(B) wherein R' is Cl_lo alkyl, C14 lower alkyl, C3_$ cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, aralkyl including benzyl, or heterocycle.
In certain embodiments, these compounds can be further modified by reduction of the lactone, derivitization of the resulting hydroxyl and addition of a base (including purine or pyrimidine bases) to provide a 2'-fluoro-2'-branched nucleoside including 2'-deoxy-2'-fluoro-2'-C-methyl-D-ribonofuranosyl nucleoside analogues.
In one embodiment, the process of Scheme I is provided:

i O ii /~' O~ O HCY~O -= Bz000 Oõ p ,o -" Oõ'( ~ t-L'-G.
~O R1 OH 0 Rt OR ~d R1 Ho R1 BzCS R1 i 2 3 5 7 Major Major O
o Ho",o SCHEME 1 l q ~o H
O FRt 4 Minor 6 Minor wherein OR is arylsulfonate, includingp-toluenesulfonate (tosylate), alkylsulfonate including methanefulfonate (mesylate), trifluoromethanesulfonate (triflate), allylsulfonate, 4-nitrobenzenesulfonate (nosylate), 4-bromobenzenesulfonate (brosylate), acetate, trifluoroacetate, arylsulfate, or alkylsulfate; and R' is C1_10 alkyl, C14 lower alkyl, C3.8 cycloalkyl, alkenyl including vinyl, alkynyl, including acetylene, allenyl, CF3, cyano, aryl, benzyl, or heterocycle.
In a subembodiment, OR is triflate and R' is lower alkyl. In another subembodiment, R' is methyl. In still another subembodiment, OR is mesylate.
In another subembodiment, OR is triflate and R' is acetylene. In yet another subembodiment OR is triflate and R' is vinyl.
In another embodiment, the process of Scheme II is provided:

O ii O Ha~~~O 'V BzO~O
0,,, p Q,~O ---~
~ Ri RiX ~'O F R' R' HO Bz0 Major Major + +
X is halogen O HO\ rp O
' SCHEME It O'" '11"~~

I O' Ho F R1 4 Minor ~ 6 Minor wherein X is chloro, bromo, iodo or fluoro. The stereochemistry at the 2-position of the lactone is inverted as the result of the displacement of the halogen group by fluoride; and R' is Cl_lo alkyl, C1.4 lower alkyl, C3.$ cycloalkyl, alkenyl including vinyl, alkynyl, including acetylene, allenyl, CF3i cyano, aryl, benzyl, or heterocycle.
In a subembodiment, X is chloro and R' is methyl. In another subembodiment, X is bromo and R' is methyl. In another subembodiment, X is chloro or bromo and R' is acetylene. In yet another subembodiment, X is chloro or bromo and R' is vinyl.
In one embodiment, the process of Scheme IIIA is provided:

i U O ii ~~ , O HO'~~O Bz0'O
~O C~O OlõC=~
O"' ~O c OH ~O : OR ~O F HO Bz0 F
1 2 3 Major 5 Major 7 SCHEME IIIA

wherein OR is arylsulfonate, including p-toluenesulfonate (tosylate), alkylsulfonate including methanefulfonate (mesylate), trifluoromethanesulfonate (triflate), allylsulfonate, 4-nitrobenzenesulfonate (nosylate), 4-bromobenzenesulfonate (brosylate), acetate, trifluoroacetate, arylsulfate, or alkylsulfate.
In another embodiment, the process of Scheme IIIB is provided:

iv - O
0,,,\/,~ O 0,, O O HO~ Sz00 O = X 1-0 F HO F Bz0 2- 3 Major 5 Major 7 SCHEME IIIB

wherein X is halogen.
In one specific embodiment, the process of Scheme IV is provided:

O O ij .. O III ~ HO'~{OO ~V . BzO~o 0,.,0 0,,,~0 O~~ O
OH ~O = OTf ~O~ HO B0 ft ~ 2 3 MaJor 5 Major 7 + +
O
0,,,~0 HO".O
!'p HO
SCHEME IV 4 Minor 6 Minor wherein OTf is triflate.
In any of the above schemes, in one embodiment steps i and ii and are carried out under anhydrous conditions. In certain embodiments, the reagents are all anhydrous, including all starting materials and solvents. The introduction of the fluoro atom to the 1,5-lactone is achieved stereospecifically with inversion at the carbon. The stereochemistry of the desired product is controlled by the stereochemistry of the starting lactone.

The use of tris(dimethylamino)sulfonium difluorotrimethyl silicate (TASF) as the fluorinating agent in specific amounts of equivalents and in a specific method of addition to the reaction mixture, i.e., lack of exposure to atmospheric conditions due to the hygroscopic nature of TASF, results in the formation of 2-fluoro-3,4-0-isopropylidene-2-C-methyl-D-ribono-l,5-lactone as the major product, rather than the elimination byproduct 4. The 2-fluoro-3,4-O-isopropylidene-2-C-methyl-D-ribono-1,5-lactone then can be converted to 2-deoxy-2-halo-2-C-methyl-D-ribono-1,4-lactone as a major product by treatment with acid. 2-deoxy-2-halo-2-C-methyl-D-ribono-l,5-lactone is formed as a minor byproduct.
Step i:
Often hydroxy groups on a reactant molecule can be prevented from participating in a reaction by using protecting groups known to those of skill in the art and as taught, for example, by Greene and Wuts, Protective Groups in Organic Synthesis (1999), Third Ed., John Wiley & Sons, Inc., New York, NY. Common hydroxy-protecting groups include ethers, esters, particularly benzoyl groups.
In one embodiment, the 2-OH group of a 3,4-0-isopropylidene-2-C-methyl-D-arabinono-l,5-lactone is converted to an leaving group to facilitate substitution with a halogen atom. In one embodiment, the preparation of the 2-OR leaving group is formed under anhydrous conditions. The temperature can be reduced to below 0 C, in certain embodiments to below -10 C, below -20 C, below -30 C or below -40 C.
In one embodiment, the leaving group OR is arylsulfonate, includingp-toluenesulfonate (tosylate), alkylsulfonate including methanefulfonate (mesylate), trifluoromethanesulfonate (triflate), allylsulfonate, 4-nitrobenzenesulfonate (nosylate), 4-bromobenzenesulfonate (brosylate), acetate, trifluoroacetate, arylsulfate, or alkylsulfate. Starting compounds for the synthesis of this invention can be obtained commercially. For example, 3,4-0-isopropylidene-2-C-methyl-D-arabinono-1,5-lactone, is obtainable commercially from a company such as Prime Organics Ltd.
Other compounds that can be used as starting materials for this process include protected 2-C-methyl-D-arabinono-1,4-lactone.
Step ii:

In certain embodiments, a halogen substituted compound is used as starting material and is commercially obtained. In these instances, a separate step to include a leaving group (i.e. step i) is not required.
The 2-C-methyl-1,5-lactone product of step i or a commercially available 2-C-methyl-2-halogenated-l,5-lactone is reacted with a fluorinating agent, under conditions that allow substitution of the leaving group. This reaction is typically carried out under anhydrous conditions. In one embodiment, the reaction contains less than 1 f , less than 0.1%, or less than 0.01 0 water.
In one embodiment, the fluorinating agent is tris(dimethylamino)sulfonium difluorotrimethyl silicate (TASF). Other, less preferred fluorinating agents include but are not limited to HF, HF-amine complexes, including HF-pyridine, sulfur tetrafluoride, KF, KF/crown ether, CaF, LiF, NaF, silver(I) fluoride, CsF, antimony (III) fluoride, antimony (V) fluoride, n-Bu4NF, cyanuric fluoride, tetrabutylammonium difluorotriphenylstannate, (diethylamino)sulfur trifluoride (DAST), morpholinosulfur trifluoride (Morpho-DAST), N,N-diethyl-1,l,2,3,3,3-hexafluroropropylarnine, N,N-diethyl-1,2,3,3,3-pentafluroropropenamine, N,N-diethyl(2-chloro-1,1,2-trifluoroethyl)-amine and tetrabutylammonium difluorotriphenyl stannate.
Suitable solvents include dichloromethane, toluene, tetrahydrofuran, 1,4-dioxane, ethyl ether, acetonitrile, tert-butylmethyl ether (TBME), 2-methyl THF, dichloroethane, chloroform, isopropyl ether, xylenes, dimethoxy ethane, diethoxy methane.
This reaction is typically carried out at about equal to or less than 0 C, typically at less than -2 C, about -5 C, less than -5 C, about -10 C, or less.
In one embodiment, the halogenating agent is added after conversion of an arabino-l,5-lactone to a ribono-l,5-lactone. In one embodiment, the temperature is increased to about 0 C after contact with the halogenating agent. The substitution reaction is stereospecific, occurring with inversion at the carbon.

Step iii:
A 2-halo-2-C' substituted-D-ribono-l,5-lactone can be converted to 2-deoxy-2-halo-2-C-substituted-D-ribono-l,4-lactone by contacting the compound with an acid.
The reaction produces a mixture of 1,4-lactone as the major product, with a 2-halo-3,4-O-isopropylidene-2-C-substituted-D-ribono-1,5-lactone as the minor product. This reaction can be conducted at room temperature.
In one embodiment, the acid is an organic acid. Suitable acids include but are not limited to trifluoroacetic acid, trichloroacetic acid, acetic acid, methylsulfonic acid, p-toluenesulfonic acid, and trifluoromethylsulfonic acid. In one embodiment, the acid is an organic acid. In one subembodiment, the acid is trifluoroacetic acid.
In certain embodiments, the deprotection is carried out for longer time periods and additional acid is added to maximize the formation of product. For example, in one embodiment, to provide the 1,4-lactone intermediate in greatest yields, deprotection reaction time can be increased from what was previously used. In addition, additional TFA(trifluoroacetic acid )/H2 /dioxane can be added, and the acetone byproduct can be removed by vacuum distillation to drive the reaction over its equilibrium point.

Step iv:
The 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone can be used in a continuous synthesis to fortn a fluoro-containing nucleoside analogue. Hydroxy groups on a reactant molecule can be blocked from participating in a reaction by using protecting groups known to those of skill in the art and as taught, for example, by Greene and Wuts, Protective GrouRs in Organic Synthesis (1999), Third Ed., John Wiley & Sons, Inc., New York, NY. Carnmon hydroxy-protecting groups.include ethers, esters, and particularly benzoyl groups. Benzoyl chloride can easily and effectively be added to a ribonolactone intermediate in the presence of a base, to provide a 3,5-di-benzoyl protected ribonolactone.
In one embodiment, the steps for protection include: dissolving 2-deoxy-2-fluoro-2-C-methyl-D-ribono-l,4-lactone in pyridine and cooling the resulting solution to about 0 C under an inert atmosphere, including an argon or nitrogen atmosphere, adding benzoyl chloride dropwise over a short time, and then bringing the resulting solution to room temperature and stirring for about 3-5 hours. Additional benzoyl chloride then is added and the solution stirred for about 15-20 hours, after which a fixrther amount of benzoyl chloride is added. The solution is stirred about another 2-4 hours, a final portion of benzoyl chloride added, and the solution was aged for about another hour. The reaction is then quenched by the addition of water, and the solids formed during the reaction are dissolved. After stirring the solution for about 5 minutes, crystals precipitate from the solution. The crystals are filtered and washed with water. The resulting solid is dissolved in dichloromethane and washed with an HCI solution. The organic layer produced from the dichloromethane/HC1 treatment is dried, filtered and concentrated in vacuo to afford an off-white residue. The residue is purified by flash chromatography to provide 3,5-diben.zoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone.
In an alternate embodiment, a process is provided for preparing a compound of Formula (I), which is a key intermediate in the synthesis of certain nucleoside analogues, including 2'-branched nucleoside analogs.
O
HOun 0 ~~~ R
MO X' 1 (I) wherein R' is Ct-to alkyl, C1-4 lower alkyl, C3_$ cycloalkyl, alkenyl including vinyl, alkynyl including acetylene, allenyl, CF3, cyano, aryl, aralkyl including benzyl, or heterocycle; and Xl is halogen.
In one embodiment, the present invention further provides a process for preparing a compound of Formula (A), which*is a key interinediate in the synthesis of certain nucleoside analogues, including 2'-branched nucleoside analogs.

HO : - RHO j~, ~
(A) wherein R' and Xi are as defined above.

Identity of all product compounds described below was confirmed by extensive NMR, MS, IR, optical rotation a-D, melting point, CHN elemental analysis, and/or crystal structure determinations.
Examples Example 1. 3,4-O-Isopropylidene-2-C-methyl-2-O-trifluoromethanesulfonyl-D-arabinono-1,5-lactone p = OTf 3,4-O-Isopropylidene-2-C-methyl-D-arabinono-1,5-lactone (7.09g, 0.03 5mol) was dissolved in anhydrous dichloromethane (110m1). Anhydrous pyridine was added (25.5m1, 0.315mo1) to the solution, which was then cooled to -40 C
under an argon atmosphere. Trifluoromethanesulfonic anhydride (28.4m1, 0.168mo1) or triflate was added dropwise over 0.5h. The mixture was allowed to warm slowly to -10 C over 3.5h, after which time the color became deep red and t.l.c. (ethyl acetate/heptane, 1:2) indicated conversion of starting material (Rf 0.33) to a major product (Rf 0.55). The reaction mixture was diluted with dichloromethane (506m1) and washed with 1M HClaq (280m1). The aqueous layer was extracted with dichloromethane (200m1 x 2) and the combined organic layers were washed with brine (400m1), dried (magnesium sulfate), filtered and concentrated in vacuo.
The crude red/brown triflate (9.5g) was purified by flash column chromatography (loaded from dichloromethane, eluted with heptane then ethyl acetate/heptane, 1:5) to give 3,4-O-isopropylidene-2-C-methyl-2-Ortrifluoromethanesulfonyl-D-arabinono-l,5-lactone (5.51 g, 47%) as a white solid.
Data for C10H13F307S 334.27gmo1"1; Rf = 0.33, ethyl acetate/heptane, 1:5; iH
NMR
SH (400 MHz, CDCl3) : 1.37, 1.44 (6H, 2 x s, C(CH3)2), 1.98 (3H, s, CH3), 4.55 (1H, a-d, J$,5- 13.0, H-5), 4.62 (1H, a-d, J7.2, H-4), 4.70 (1H, a-d, .I9.2, H-3), 4.76 (1H, dd, J5"5 13.0, J5,4 1.7, H-5').

Example 2. 2-Deoxy-2-fluoro-3,4-O-isopropylidene-2-C-methyl-D-ribono-1,5-lactone O
0.,t 0 ,( ~. _ ~f'O F
3,4-O-isopropylidene-2-C-methyl-2-O-trifluoromethanesulfonyl-D-arabinono-1,5-lactone (5.48g, 0.0164mo1) was dissolved in anhydrous dichloromethane (56m1) giving a pale yellow solution which was cooled to -5 C
under an argon atmosphere. Tris(dimethylamino)sulfur trimethylsilyl difluoride, TASF, (3 x 5g, 0.0538mo1) was added to the solution directly from the bottles due to its very hygroscopic nature. The solution was stirred at 0 C for 5rnin then allowed to warm to room temperature for lh. T.l.c. (ethyl acetate/heptane, 1:1) indicated complete conversion of the starting material (Rf 0.72) to a major, but faint product (Rf 0.30). The reaction mixture was diluted with dichloromethane (420m1) and washed with water (220m1 x 2). The organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo. The crude brown residue (4.4g) was purified by flash column chromatography (loaded from dichloromethane, eluted with heptane then ethyl I5 acetate/heptane, 1:2) to give 2-deoxy-2-fluoro-3,4-O-isopropylidene-2-C-methyl-D-ribono-1,5-lactone (1.36g, 42%) as a white solid.

Data for C9H13FO4 204.20gmol"1; Rf = 0.30, ethyl acetate/heptane, 1:1; 1H NMR
SH
(400 MHz, CDC13) : 1.34, 1.51 (6H, 2 x s, C(CH3)2), 1.66 (3H, d, JH,F 22.5, CH3), 4.39 (IH, dd, J5,5' 13.3, J5,4 2.4, H-5), 4.48 (1H, dd, J5,,5 13.3, J5.,4 0.9, H-5'), 4.56-4.61 (2H, m, H-3, H-4); 13C NMR Sc (100 MHz, CDC13) : 19.46 (d, 2JC,F 26.1, CH3), 24.62, 26.31 (C(CH3)2), 68.93 (C-5), 71.84 (d, 3JC,F 4.6, C-4), 78.18 (d, 2Jc,F 16.8, C-3), 89.82 (d, 1JC,F 192.5, C-2), 111.49 (C(CH3)2), 168.1 (d, 2JC,F 25.1, C=O);

NMR SF (376 MHz, CDCl3) : -159.80 (1F, m, 3JF,x 22.9, F). NMR assignments confirmed using COSY and HMQC experiments; Mass Spec m/z (APCI-) : 203.3 ([M-H]-, 50%), 236.3 (100%).

Example 3. Data for 2-deoxy-2-fluoro-2-C-methyl-D-ribono-l,5-lactone O
HOnri 0 H01%~ F

(C6H9F04) 164.13gmo1'1;
Rf= 0.45, ethyl acetatefheptane, 8:1; m.p. : 119-120 C then 133-135 C'; (a]D2o :
+115.025 (c, 0.9284 in CH3CN); vm9,, (KBr disc) : 3414cm 1, 3276crri 1(O-H), 1778cxri ' (C=0); 'H NMR 8n (400 MHz, CD3CN) : 1.57 (3H, d, JH,F 23.7, CH3), 2.19 (1H, br-s, OH), 4.04 (1H, dd, 3JH,F 22.5, .T3,4 7.6, H-3), 4.12 (1H, br-s, OH), 4.54 (1H, dd, J5,5- 12.4, Js,a 6.3, H-5), 4.61 (1H, dd, J4,3 7.6, J4,5 6.3, J4,5, 2.0, H-4), 4.80 (1H, dd, J5,,5 12.4, J5,,4 2.0, H-5');13C NMR 6c (1001VIHz, CD3CN) : 17.18 (d, 2JC,F
24.5, CH3), 66.56 (C-5), 72.43 (d, 2Jc,F 16.9, C-3), 79.61 (C-4), 92.98 (d, 1Jo,F 179.5, C-2), 171.00 (d, ZJc,F 21.5, C--O);19F NMR SF (376 MHz, CD3CN) : -169.28 (1F, m, 3JF,H 22.9, F). NMR assignments confirmed using COSY, HMQC, HMBC and nOe experiments; Mass Spec'rWz (APCI-)' i 163.2 ([M-H]", 30%), 143.2 (100%).

Example 4. 2-Deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone HO

HO
2-Deoxy-2-fluoro-3,4-(?-is opropylidene-2-e-methyl-D-ribono-1,5-lactone (1.29g, 6.317mmo1) was dissolved in anhydrous 1,4-dioxane (36.7m1) under an atmosphere of argon. A pre-mixed solution of trifluoroacetic acid (146.8m1) in water (36.7m1) was added to the mixture slowly at room temperature. After 48h, t.l.c. (ethyl acetate/heptane, 3:1) indicated conversion of the starting material (Rf 0.57) to faint products (Rf 0.47, 0.43, 0.38). The solvents were removed in vacuo at 35 C and then coevaporated with toluene (5m1 x 2). 'The crude off-white/brown residue (1.27g) was purified by.flash column chromatography (pre-adsorbed onto silica from ethyl acetate, eluted with ethyl acetate/heptane, 2:1) to give 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone (862mg, 83%, eluted second) as a white solid and 2-deoxy-2-Possible contamination with residual TFA:

fluoro-2-C methyl-D-ribono-1,5-lactone '(61mg, 6%, eluted first) as a white solid, along with mixed fractions (I 15mg, 11%).

Data for 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone C6H9FO4 164.13gtnol-1; Rf = 0.45, ethyl acetate/heptane, 8:1; m.p. : 142-143 C; [a]D2o :
+129.323 (c, 0.9138 in CH3CN); vme1X (KSr disc) : 3412cni ', 3274cm"' (0-H), 1777cm"l (C-0); 'H NMR fiH (400 MHz, CD3CN) : 1.55 (3H, d, JH,F 23.5, CH3), 2.22 (1H, br-s, OH), 3.17 (1H, br-s, OH), 3.69 (1H, dd, J5,5, 13.3, J5,4 3.7, H-5), 3.92 (1H, dd, J5,,5 13.3, J5,,4 1.5, H-5'), 4.05 (1H, dd, 3J,,,r 21.5, J3,4 7.2, H-3), 4.32 (1H, m, H-4); 13C NMR Sc (100 MHz, CD3CN) : 17.63 (d, 2JC,F 25.3, CH3), 60.19 (C-5), 71.85 (d, 2Jc,r 16.9, C-3), 83.94 (C-4), 94.55 (d, 1Jcr 178.7, C-2), 172.04 (d, 2JC,F
21.5, C=0); ;9F NMR SF (376 MHz, CD3CN) :-168.69 (i F, m, 3JF,H 23.3, F). NMR
assignments confirmed using COSY, HMQC, HMBC and nOe experiments; Mass Spec mr'z (APCI-) : 163.2 ([M-H]-, 40%), 143.2 (100%). Microanalysis : C6HgF04 calculated C 43.91 0 , H 5.53%, found C 44.18%, H 5.73%. Crystals grown from ethyl acetate/hexane.

Example 5. 3,5-12i-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone o Q
azo Bzd F
2-Deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone (200mg, 1.219mmol) was dissolved in anhydrous pyridine (2.4m1) and cooled to 0 C under an atmosphere of argon. Benzoyl chloride (353 1, 3.05mmo1) was added dropwise over 5min. The solution was allowed to warm to roorn temperature and stirred for 4h. Benzoyl chloride (142 1, 1.219mmol) was added diopwise and the mixture was stirred for 16h after which time a further portion of benzoyl chloride (142 1, 1.219mmol) was added.
Having stirred the solution for a fitrther 3h, a final portion of benzoyl chloride (142}Ll, 1.219mmol) was added and left for a further 1 h. T.l.c. (ethyl acetate/heptane, 2:3) indicated complete conversion of the starting material (Rr 0.16) to faintly stained, but UV active products (Rf 0.67, 0.63). The reaction was quenched with water (lrnl) and the solids dissolved. After stirring at room temperature for 5min crystals precipitated from the solution which were filtered and washed with water (2ml x 2) and found by t.l.c. to contain two UV active components and pyridine. The dried, sticky solid (400mg) was therefore dissolved in dichloromethane (10m1) and subjected to a IM
HClaq (4m1 x 2) wash. The organic layer was dried (magnesium sulfate), filtered and concentrated in vacuo. The crude off-white residue (340mg) was purified by flash column chromatography (pre-adsorbed onto silica from dichloromethane, eluted with ethyl acetate/heptane, 1:4) to give 3,5-di-benzoyl-2-deoxy-2-fluoro-2-C methyl-D-ribono-1,4-Iactone (272mg, 60%) as fine, white needles.

Data for 3,5-di-benzoyl-2-deoxy-2-fluoro-2-C-methyl-ID-ribono-1,4-lactone C2oH17F06 372.34gmo1'1; Rf = 0.62, ethyl acetate/heptane, 2:3; m.p. : 123-125 C;
[a]o20 : +102.943 (c, 0.8728 in CH3CN); vma,, (thin film) : 1793cm"'(C=O, a-fluoro-y-lactone), 1733em", 1717cm"1 (C=O, Bz); 'H NMR B. (400 MHz, CD3CN) : 1.74 (3H, d, Jn,F 24.1, CH3), 4.62 (1H, dd, JS,5' 12.7, J5,4 5.6, H-5), 4.75 (1H, dd, J5=,5 12.7, J5,,4 3.5, H-5'), 5.07 (1H, ddd, J4,3 7.2, J4,5 5.6, J4,5> 3.5, H-4), 5.62 (1H, dd, 3JH,F 17.7, J3,4 7.2, H-3); 7.48, 7.55 (4H, 2 x t, 4 x Hmeta), 7.64, 7.70 (2H, 2 x t, 2 x Hpa,."), 8.01, 8.09 (4H, 2 x t, 4 x Ho~o); 13C NMR 6, (100 MHz, CD3CN) : 18.88 (d, ''JC,F
24.5, CH3), 63.51 (C-5), 73.07 (d, 2Jl;,F 14.6, C-3), 78.84 (C-4), 92.61 (d, 'Jc,F
185.6, C-2), 129.51, 130.53 (2 x Cips ), 129.64, 129.78 (2 x Cmeta), 130.43, 130.76 (2 x Cortho), 134.46, 135.00 (2 x Cpam), 166.22, 166.63 (2 x eO2Bz), 170.64 (d, 2JC,F 21.0, C'--O);
19F NMR 8F (376 MHz, CD3CN) :-164.77 (1F, ln, 3JF,H 24.4, F). NMR assignments confirmed using COSY, HMQC, HMBC and nOe experiments; Mass Spec rnlz (ESI-) : 373.1 ([M+H]+, 50%), 390.2 ([1VI+NH4]+, 100%); HPLC (272nm) Rt = 6.17 (98%); Microanalysis : C2aH17F06 calculated C 64.51 %, H 4.60%, found C
64.56%, H 4.66%.
The foregoing merely is illustrative of the invention and is not intended to limit the invention to the disclosed processes and reaction conditions.
Variations that are obvious to one of ordinary skill in the art are intended to be included within the spirit and scope of the invention as defined in the appended claims

Claims (37)

1. A process of preparing a compound of Formula II

wherein R1 is straight chained, or branched alkyl, cycloalkyl, alkenyl, alkynyl, allenyl, CF3, cyano, aryl, aralkyl, or heterocycle comprising:
a) providing a compound of structure (i) or (ii) where OR is a leaving group and X is halogen;
b) contacting the compound with a fluorinating agent under anhydrous conditions;
and c) removing the hydroxyl protecting group from the product of step b).
2. The process of claim 1 wherein the fluorinating agent is tris(dimethylamino)sulfonium difluorotrimethyl silicate (TASF).
3. The process of claim 1 wherein a compound of Formula (II) is produced in at least 40% or more yields.
4. The process of claim 1 wherein R1 is methyl.
5. The process of claim 1 wherein R1 is ethyl.
6. The process of claim 1 wherein R1 is vinyl.
7. The process of claim 1 wherein R1 is -C.ident.CH.
8. The process of claim 1 wherein OR is selected from the group consisting of triflate, mesylate, and tosylate.
9. The process of claim 1 wherein X in Formula (ii) is bromine, chlorine or iodine.
10. The process of claim 8 wherein OR is triflate.
11. The process of claim 1 wherein the reaction contains less than 1% water.
12. The process of claim 1 wherein the reaction contains less than 0.1% water.
13. The process of claim 1 wherein the reaction contains less than 0.01%
water.
14. The process of claim 1 further comprising converting a compound of Formula (II) to a 1,4-lactone compound.
15. The process of claim 14 comprising:
c) contacting the product from step (b) with an organic acid in an organic solvent.
16. The process of claim 15 wherein the acid is trifluoroacetic acid.
17. The process of claim 15 wherein the acid is an aryl or alkyl sulfonic acid.
18. The process of claim 17 wherein the acid is methanesulfonic acid.
19. The process of claim 17 wherein the acid is p-toluenesulfonic acid.
20. The process of claim 15 wherein the solvent is 1,4-dioxane.
21. The process of claim 14 wherein 1,4-lactone compound is compound of Formula (B) wherein R1 is C1-4 lower alkyl, alkenyl, alkynyl or CF3.
22. The process of claim 14 wherein the 1,4-lactone compound is a 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone.
23. The process of claim 21 wherein R1 is acetylene.
24. The process of claim 21 wherein R1 is vinyl.
25. The process of claim 1 further comprising:
d) reducing the 1,5-lactone to a hemiacetal, e) derivitizing the hydroxyl from step d) to a suitable leaving group; and f) contacting the 1,4-lactone product of step (e) with a purine or pyrimidine base to provide a 2'-branched nucleoside compound.
26. The process of claim 1, wherein the compound of Formula (i) is 3,4-O-isopropylidene-2-C-methyl-2-O-trifluoromethanesulfonyl-D-arabinono-1,5-lactone.
27. The process of claim 1 wherein a 2-deoxy-2-fluoro-3,4-O-isopropylidene-2-C-methyl-D-ribono-1,5-lactone is produced.
28. The process of claim 25 wherein a 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone is produced.
29. The process of claim 1 wherein the fluorinating agent is TASF.
30. The process of claim 1 wherein step (b) is carried out less than 0°C.
31. The process of claim 1 wherein step (b) is carried out at less than -5°C.
32. A process for preparing a 2-deoxy-2-alkyl-2-halo-lactone compound comprising:
a) reacting an isopropylidene, alkyl-substituted arabinono-1,5-lactone compound to provide a 2-deoxyalkyl-disubstituted isopropylidene arabinono-1,5-lactone substituted with a leaving group at the 2-position;
b) reacting the product from step a) with a fluorinating agent to provide a 2-deoxy-2-fluoro, alkyl-disubstituted isopropylidene ribono-1,5-lactone;
c) deprotecting the product from step b) to provide a 2-deoxy-2-fluoro, alkyl-disubstituted ribono-1,4-lactone as a major product and a 2-deoxy-2-fluoro, alkyl-disubstituted ribono-1,5-lactone as a minor product; and d) optionally protecting one or more hydroxy groups on either one of the products from step c.
33. The process of claim 32, step a) wherein the 2-deoxy-2-triflate, alkyl-disubstituted isopropylidene arabinono-1,5-lactone is 3,4-O-isopropylidene-2-C-methyl-2-O-trifluoromethanesulfonyl-D-arabinono-1,5-lactone.
34. The process of claim 32, step b) wherein the 2-deoxy-2-triflate, alkyl-disubstituted isopropylidene arabinono-1,5-lactone is 2-deoxy-2-fluoro-3,4-O-isopropylidene-methyl-D-ribono-1,5-lactone.
35. The process of claim 32, step c) wherein the 2-deoxy-2-fluoro, alkyl-disubstituted ribono-1,4-lactone major product is 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,4-lactone.
36. The process of claim 32, step c) wherein the 2-deoxy-2-fluoro, alkyl-disubstituted ribono-1,5-lactone minor product is 2-deoxy-2-fluoro-2-C-methyl-D-ribono-1,5-lactone.
37. The process of claim 32, step d) wherein benzoyl is the protecting group on one or more hydoxy groups on either of one of the products from claim 1, step c).

39. The process of claim 32 wherein the fluorinating agent is TASF.

40. The process of claim 32, step c) wherein the deprotecting reagent is trifluoroacetic acid (TFA).

41. The process of claim 32, step a) wherein the leaving group is selected from the group consisting of triflate, mesylate, bromine, chlorine or iodine.

42. The process of claim 41 wherein the leaving group compound is triflate.
CA2634749A 2005-12-23 2006-12-22 Process for preparing a synthetic intermediate for preparation of branched nucleosides Expired - Fee Related CA2634749C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75350705P 2005-12-23 2005-12-23
US60/753,507 2005-12-23
PCT/US2006/048769 WO2007075876A2 (en) 2005-12-23 2006-12-22 Process for preparing a synthetic intermediate for preparation of branched nucleosides

Publications (2)

Publication Number Publication Date
CA2634749A1 true CA2634749A1 (en) 2007-07-05
CA2634749C CA2634749C (en) 2014-08-19

Family

ID=38218604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2634749A Expired - Fee Related CA2634749C (en) 2005-12-23 2006-12-22 Process for preparing a synthetic intermediate for preparation of branched nucleosides

Country Status (7)

Country Link
US (1) US7781576B2 (en)
EP (1) EP1976382B1 (en)
JP (1) JP5254033B2 (en)
CA (1) CA2634749C (en)
ES (1) ES2422290T3 (en)
HK (1) HK1123682A1 (en)
WO (1) WO2007075876A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (en) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treating flaviviruses and pestiviruses
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2014514295A (en) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (en) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP2755985B1 (en) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
CN103420955B (en) * 2012-05-23 2016-09-28 浙江瑞博制药有限公司 A kind of preparation method of fluoro ribose lactone
MX2014014323A (en) 2012-05-25 2015-02-12 Janssen R & D Ireland Uracyl spirooxetane nucleosides.
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
TR201809048T4 (en) 2012-10-08 2018-07-23 Centre Nat Rech Scient 2'-chloro nucleoside analogs for HCV infection.
CN103724301A (en) 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2R)-2-desoxy-2,2-disubstituted-1,4-ribonolactones, preparation method and purpose thereof
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
CN103288906A (en) * 2013-06-26 2013-09-11 湖南欧亚生物有限公司 A 3,5 - bis-O-benzoyl-2-C-methyl-C-methyl C-4 - (1,2,4 - triazolyl) uridine and a synthesis method thereof
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN105418547A (en) * 2015-11-17 2016-03-23 海门慧聚药业有限公司 Preparation for sofosbuvir key intermediate
CN106083961B (en) * 2016-07-13 2019-02-22 南通常佑药业科技有限公司 A kind of preparation method of the fluoro- 2 '-methylurea glycosides of (2 ' R) -2 '-deoxidations -2 ' -
CN106366057B (en) * 2016-08-25 2019-05-14 安徽华昌高科药业有限公司 A kind of synthetic method of Suo Feibuwei intermediate

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US3074929A (en) 1955-08-11 1963-01-22 Burroughs Wellcome Co Glycosides of 6-mercaptopurine
GB924246A (en) 1958-12-23 1963-04-24 Wellcome Found Purine derivatives and their preparation
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
GB984877A (en) 1962-08-16 1965-03-03 Waldhof Zellstoff Fab Improvements in and relating to 6-halonucleosides
GB1163103A (en) 1965-11-15 1969-09-04 Merck & Co Inc Ribofuranosyl Purine Derivatives
FR1498856A (en) 1965-11-15 1968-01-10
FR1521076A (en) 1966-05-02 1968-04-12 Merck & Co Inc Substituted purine nucleosides
DE1695411A1 (en) 1966-05-02 1971-04-15 Merck & Co Inc Substituted purine nucleosides and processes for their preparation
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
DE2122991C2 (en) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Process for the preparation of cytosine and 6-azacytosine nucleosides
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4022889A (en) 1974-05-20 1977-05-10 The Upjohn Company Therapeutic compositions of antibiotic U-44,590 and methods for using the same
DE2508312A1 (en) 1975-02-24 1976-09-02 Schering Ag NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
US4058602A (en) 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
DE2757365A1 (en) 1977-12-20 1979-06-21 Schering Ag NEW PROCESS FOR THE PRODUCTION OF NUCLEOSIDES
DE2852721A1 (en) 1978-12-06 1980-06-26 Basf Ag METHOD FOR REPRESENTING POTASSIUM RIBONATE AND RIBONOLACTONE
US4239753A (en) 1978-12-12 1980-12-16 The Upjohn Company Composition of matter and process
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562543B1 (en) 1984-04-10 1987-09-25 Elf Aquitaine NOVEL CYCLIC PHOSPHONITES, THEIR PREPARATION AND APPLICATIONS
NL8403224A (en) 1984-10-24 1986-05-16 Oce Andeno Bv DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS.
JPS61204193A (en) 1985-03-05 1986-09-10 Takeda Chem Ind Ltd Production of cytosine nuceoside
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4605659A (en) 1985-04-30 1986-08-12 Syntex (U.S.A.) Inc. Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals
US4754026A (en) 1985-06-04 1988-06-28 Takeda Chemical Industries, Ltd. Conversion of uracil derivatives to cytosine derivatives
DE3714473A1 (en) 1987-04-30 1988-11-10 Basf Ag CONTINUOUS PROCESS FOR EPIMERIZING SUGAR, ESPECIALLY FROM D-ARABINOSE TO D-RIBOSE
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
SE8802687D0 (en) 1988-07-20 1988-07-20 Astra Ab NUCLEOSIDE DERIVATIVES
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5616702A (en) 1988-11-15 1997-04-01 Merrell Pharmaceuticals Inc. 2-'-ethenylidene cytidine, uridine and guanosine derivatives
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5021562A (en) * 1989-05-15 1991-06-04 Monsanto Company Method for azide displacement of α-triflates of 1,5-lactones
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5200514A (en) 1990-01-19 1993-04-06 University Of Georgia Research Foundation, Inc. Synthesis of 2'-deoxypyrimidine nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
FR2662165B1 (en) 1990-05-18 1992-09-11 Univ Paris Curie BRANCHED NUCLEOSIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS.
CA2083961A1 (en) 1990-05-29 1991-11-30 Henk Van Den Bosch Synthesis of glycerol di- and triphosphate derivatives
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
JPH04266880A (en) 1991-02-22 1992-09-22 Japan Tobacco Inc Production of 3-dpa-lactone
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
JPH0525152A (en) 1991-07-22 1993-02-02 Japan Tobacco Inc Production of 3-dpa-lactone
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (en) 1991-09-13 1994-05-21 Paul B Chretien
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401861A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5256797A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
DE4224737A1 (en) 1992-07-27 1994-02-03 Herbert Prof Dr Schott New cytosine analogues with lipophilic protected amino gps. - for treatment of cancer and virus diseases e.g. AIDS, are more protected against enzymatic des-amination and can be used in higher doses than unprotected cpds.
IL106840A (en) 1992-09-01 1998-09-24 Lilly Co Eli Process for basic anomerization of pentofuranosyl nucleosides
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
AU674639B2 (en) 1994-12-13 1997-01-02 Akira Matsuda 3'-substituted nucleoside derivatives
DE19513330A1 (en) 1995-04-03 1996-10-10 Schering Ag New process for the production of nucleosides
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
ATE459361T1 (en) 1995-09-07 2010-03-15 Univ Georgia THERAPEUTIC AZIDE COMPOUNDS
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
SK284054B6 (en) 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
NZ335000A (en) 1996-10-28 2000-12-22 Univ Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DE69933860T2 (en) 1998-02-25 2007-05-31 Emory University 2'-FLUORONUKLEOSIDE
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
KR100389853B1 (en) 1998-03-06 2003-08-19 삼성전자주식회사 Method for recording and reproducing catalog information
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
CN1170543C (en) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 Use of PEG-IFN-alpha and triazole nucleoside for treatment of chronic hepatitis C
MXPA01001507A (en) 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd beta-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B.
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2252144A1 (en) 1998-10-16 2000-04-16 University Of Alberta Dual action anticancer prodrugs
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
KR100618028B1 (en) 1998-11-05 2006-08-30 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 Nucleosides with anti-hepatitis B virus activity
AU777040B2 (en) 1999-02-22 2004-09-30 Shire Biochem Inc. (1,8) naphthyridine derivatives having antiviral activity
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP1210354A1 (en) 1999-09-08 2002-06-05 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
BR0017048A (en) 1999-12-22 2002-11-05 Metabasis Therapeutics Inc Phosphonate bisamidate prodrugs
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7056895B2 (en) 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
CA2400274A1 (en) 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
BR0110023A (en) 2000-04-13 2003-12-30 Pharmasset Ltd Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
DE60105424T2 (en) 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. METHODS FOR TREATING DELTA HEPATITIS VIRUS INFECTIONS WITH BETA-L-2 'DEOXY NUCLEOSIDES
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
KR20080021797A (en) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
KR100426030B1 (en) * 2000-07-22 2004-04-03 (주) 한켐 Chirality conversion method in lactone sugar compounds
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20040028657A (en) 2000-10-18 2004-04-03 파마셋, 리미티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP1360325A2 (en) 2000-10-18 2003-11-12 Pharmasset Limited Multiplex quantification of nucleic acids in diseased cells
MXPA03003456A (en) 2000-10-18 2003-07-14 Schering Corp Ribavirin-pegylated interferon alfa hcv combination therapy.
CN1527836A (en) 2000-12-15 2004-09-08 Antiviral agents for treatment of flaviviridae infections
AU2002243791B2 (en) 2001-01-22 2006-06-29 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
CA2439836A1 (en) 2001-03-01 2002-09-12 Pharmasset Ltd. Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000200A2 (en) 2001-06-22 2003-01-03 Pharmasset Ltd. β-2'-OR 3'-HALONUCLEOSIDES
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
JP2005536440A (en) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of flaviviruses and pestiviruses using nucleosides modified at the 4 'position
US7105527B2 (en) 2001-12-14 2006-09-12 Otto Michael J N4-acylcytosine nucleosides for treatment of viral infections
NZ534811A (en) 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management Nucleotide mimics and their prodrugs
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp Nucleoside derivatives for treating hepatitis c virus infection
US7094768B2 (en) 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
MXPA05005192A (en) 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1745573A4 (en) 2003-03-20 2010-05-26 Microbiol Quimica Farmaceutica Methods of manufacture of 2 -deoxy- beta-l-nucleosides
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
SI3521297T1 (en) 2003-05-30 2022-04-29 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
DK1644395T3 (en) 2003-06-19 2007-04-02 Hoffmann La Roche Process for Preparation of 4azido Nucleoside Derivatives
KR20060035652A (en) * 2003-06-30 2006-04-26 이데닉스 (케이만) 리미티드 SYNTHESIS OF beta-L-2-DEOXY NUCLEOSIDES
US7151089B2 (en) 2003-10-27 2006-12-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
AU2004295291A1 (en) 2003-10-27 2005-06-16 Smithkline Beecham Corporation Nucleoside compounds for treating viral infections
CA2542776A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
DE602005015466D1 (en) 2004-08-23 2009-08-27 Hoffmann La Roche ANTIVIRAL 4'-AZIDONUCLEOSIDE
ES2725457T3 (en) * 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
DE102005012681A1 (en) 2005-03-18 2006-09-21 Weber, Lutz, Dr. New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides

Also Published As

Publication number Publication date
JP2009521465A (en) 2009-06-04
CA2634749C (en) 2014-08-19
WO2007075876A3 (en) 2007-09-13
HK1123682A1 (en) 2009-06-26
US20070203334A1 (en) 2007-08-30
JP5254033B2 (en) 2013-08-07
ES2422290T3 (en) 2013-09-10
WO2007075876A2 (en) 2007-07-05
EP1976382A4 (en) 2011-11-23
EP1976382A2 (en) 2008-10-08
EP1976382B1 (en) 2013-04-24
US7781576B2 (en) 2010-08-24

Similar Documents

Publication Publication Date Title
CA2634749C (en) Process for preparing a synthetic intermediate for preparation of branched nucleosides
CA2574651C (en) Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
ES2769377T3 (en) D-ribonolactone intermediates with 2-fluoro-2-alkyl substitution
KR860001283B1 (en) Method of preparing difluoro antivirals and intermediate therefor
CA2439836A1 (en) Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
MXPA05006230A (en) Process for the production of 2'-branched nucleosides.
AU2002255654A1 (en) Method for the synthesis of 2',3'-dideoxy -2',3'-didehydronucleosides
JP2008507547A5 (en)
US5283327A (en) Tri-O-acetyl-2-alkynyladenosines
JPH07300492A (en) New production of n4-acyl-5'-deoxy-5-fluoro-cytidine derivative
RU2006102518A (en) SYNTHESIS OF L-2-DESOXINUCLEOSIDES
CA2586687A1 (en) Difluoronucleosides and process for preparation thereof
JP3659989B2 (en) Stereoselective preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonate intermediates rich in β-anomer
US5432273A (en) Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors
FR2900152A1 (en) PROCESS FOR THE PREPARATION OF GEMCITABINE AND ASSOCIATED INTERMEDIATE COMPOUNDS
US6229008B1 (en) α-D-pentofuranosides, and a process for preparing the same
KR20080094890A (en) Process for preparing gemcitabine and associated intermediates
KR100446560B1 (en) Method for Producing 2-Deoxy-L-ribose
WO1995012593A1 (en) 5-0-pyrimidyl-2,3-dideoxy-1-thiofuranoside derivative, process for producing the same, and use thereof
WO2017075590A2 (en) Processes for preparing 2-dihalo ribolactones
KR20080090950A (en) Process for preparing gemcitabine and associated intermediates

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151222

MKLA Lapsed

Effective date: 20151222